Second autologous stem cell transplantation ...
Document type :
Article dans une revue scientifique: Article original
PMID :
Permalink :
Title :
Second autologous stem cell transplantation for relapsed/refractory hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the ebmt
Author(s) :
Martinez, Carmen [Auteur]
Boumendil, Ariane [Auteur]
Romejko-Jarosinska, Joanna [Auteur]
Anagnostopoulos, Achilles [Auteur]
Faber, Edgar [Auteur]
Poire, Xavier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Akhtar, Saad [Auteur]
Gurman, Gunhan [Auteur]
Pavone, Vincenzo [Auteur]
Halaburda, Kazimierz [Auteur]
Sousa, Aida Botelho [Auteur]
Ghesquieres, Herve [Auteur]
Finel, Herve [Auteur]
Khvedelidze, Irma [Auteur]
Montoto, Silvia [Auteur]
Sureda, Anna [Auteur]
Boumendil, Ariane [Auteur]
Romejko-Jarosinska, Joanna [Auteur]
Anagnostopoulos, Achilles [Auteur]
Faber, Edgar [Auteur]
Poire, Xavier [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Akhtar, Saad [Auteur]
Gurman, Gunhan [Auteur]
Pavone, Vincenzo [Auteur]
Halaburda, Kazimierz [Auteur]
Sousa, Aida Botelho [Auteur]
Ghesquieres, Herve [Auteur]
Finel, Herve [Auteur]
Khvedelidze, Irma [Auteur]
Montoto, Silvia [Auteur]
Sureda, Anna [Auteur]
Journal title :
Leukemia & lymphoma
Abbreviated title :
Leuk. Lymphoma
Pages :
1-8
Publication date :
2020-07-11
ISSN :
1029-2403
Keyword(s) :
Hodgkin lymphoma
relapse
refractory
autologous hematopoietic stem cell transplantation
relapse
refractory
autologous hematopoietic stem cell transplantation
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). ...
Show more >The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). Outcomes for 56 patients receiving an ASCT2 registered in the EBMT database were analyzed. The 4-year cumulative incidences of non-relapse mortality and disease relapse/progression were 5% and 67%, respectively. The 4-year overall survival (OS) and progression-free survival (PFS) were 62% and 28%. In univariate analysis, relapse of HL within 12 months of ASCT1 was associated with a worse OS (35% versus 76%, ppppShow less >
Show more >The purpose of this study was to analyze the results of second autologous hematopoietic stem cell transplantation (ASCT2) for patients with relapsed/refractory Hodgkin lymphoma (HL) after a first transplantation (ASCT1). Outcomes for 56 patients receiving an ASCT2 registered in the EBMT database were analyzed. The 4-year cumulative incidences of non-relapse mortality and disease relapse/progression were 5% and 67%, respectively. The 4-year overall survival (OS) and progression-free survival (PFS) were 62% and 28%. In univariate analysis, relapse of HL within 12 months of ASCT1 was associated with a worse OS (35% versus 76%, ppppShow less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:47:31Z